Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

24.5%

12 terminated/withdrawn out of 49 trials

Success Rate

75.5%

-11.0% vs industry average

Late-Stage Pipeline

20%

10 trials in Phase 3/4

Results Transparency

38%

14 of 37 completed trials have results

Key Signals

14 with results8 withdrawn

Enrollment Performance

Analytics

Phase 1

27(55.1%)

Phase 3

10(20.4%)

Phase 2

9(18.4%)

N/A

3(6.1%)

49Total

Phase 1(27)

Phase 3(10)

Phase 2(9)

N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (49)

Showing 20 of 49 trials

NCT02514252Phase 2Terminated

Sublingual Fentanyl for the Management of Breakthrough Pain

Role: collaborator

NCT02751359Phase 1Completed

Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers

Role: collaborator

NCT02597478Phase 2Completed

Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea

Role: collaborator

NCT02902081Not ApplicableCompleted

Cannabidiol and Emotional Stimuli

Role: collaborator

NCT03827642Phase 1Completed

A Study to Compare Bioavailability of Naloxone Nasal Spray, Naloxone Hydrochloride (HCl) Intravenous (IV) and Intramuscular Injection (IM) in Healthy Volunteers

Role: lead

NCT03827629Phase 1Completed

A Study to Compare Bioavailability of Naloxone Nasal Spray and Naloxone Hydrochloride (HCl) Intramuscular Injection (IM) in Healthy Volunteers

Role: lead

NCT03254459Phase 2Completed

Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative Pain

Role: lead

NCT02551731Phase 2Terminated

Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms

Role: lead

NCT02318602Phase 3Completed

Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder

Role: lead

NCT01188408Phase 2Withdrawn

Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer

Role: lead

NCT02915978Phase 2Completed

Fentanyl Sublingual Spray for the Treatment of Moderate to Severe Post-Operative Pain

Role: lead

NCT02318537Phase 3Withdrawn

Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome

Role: lead

NCT02138409Phase 3Withdrawn

Fentanyl Sublingual Spray for the Treatment of Acute Procedure-related Pain in a Monitored Setting

Role: lead

NCT02318563Phase 3Withdrawn

Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome

Role: lead

NCT02634788Phase 3Completed

Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

Role: lead

NCT02310581Phase 3Terminated

Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

Role: lead

NCT02137525Phase 2Withdrawn

Study to Explore Effectiveness of Sublingual Fentanyl Spray in Emergency Department Patients With Acute Pain

Role: lead

NCT02324673Phase 1Completed

Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders

Role: lead

NCT02641340Phase 1Completed

Fentanyl Sublingual Spray in Opioid Naive Participants

Role: lead

NCT02604992Not ApplicableCompleted

Comparative Bioavailability of Dronabinol Oral Solution in Healthy Volunteers

Role: lead